Figure 5

Derazantinib and infigratinib inhibit endothelial cell cycle. Time-lapse images of sprouting ISVs of GFP+ endothelial cell nuclei and mCherry+ endothelial cell membranes in Tg(kdrl:EGFP-nls)^ubs1/Tg(kdrl:mCherry-CAAX)^s916 transgenic embryos from 26 hpf after treatment with DMSO (a–a’’’), 0.3 uM DZB (b–b’’’), 3 uM DZB (c-c’’’) or 0.3 uM INF(d–d’’’). Numbers indicate cell nuclei (i.e., 1, 2, 3,...) or cell nuclei arising after cell division (i.e., 1.1, 1.2,...). Number of mitotic endothelial cells was reduced in DZB-treated (c–c’’’) or INF-treated embryos (d–d’’’). (e) Quantitative analysis of mitotic endothelial cells in ISVs per embryo (n ≥ 10 embryos per treatment were analysed from three independent experiments). Data in e represent mean ± S.E.M. (error bars), ns: not significant, ** p < 0.01, *** p < 0.001. Statistical analysis was performed with the two-sided Mann–Whitney test. Scale bar, 20 µm. See also Figure S4 and Videos S3–S6.